🔗 Share this article

Given that the US proceeds with sweeping revisions to its vaccination guidelines, one figure appears in a surprising turn: Tracy Beth Høeg, an American of Danish descent sports physician and epidemiologist who first made her name by expressing skepticism about coronavirus vaccines throughout the pandemic and has concentrated on potential fatalities following Covid vaccination in her recent position at the US Food and Drug Administration (FDA).

Planned Changes to Childhood Immunization Program

Public health authorities were set to announce major changes to the childhood vaccine schedule recently, bringing the US with Denmark’s national calendar, sources say – a major change that would place the US out of alignment with many the global community with insufficient data for public health gain. This reveal has been pushed back until the coming year.

Rather than Vinay Prasad, Tracy Beth Høeg is listed to address the audience at the gathering. She was just designated interim head of the FDA’s CDER, the fifth appointee to head the division this calendar year.

A Shift at the Regulatory Body

The acting appointment may indicate a closer partnership between the pharmaceutical and biologics centers as Høeg and Dr. Prasad consolidate power at the agency – and it points to a renewed priority upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing certain childhood immunization guidelines in the US in order to be more similar to Denmark's approach, a country with comprehensive healthcare and a number of inhabitants approximately the population of Wisconsin’s.

To date comments, she has continued to focus on vaccination policy – usually the responsibility of Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – rather than pharmaceutical oversight.

Doubts Over Qualifications

The appointee has no apparent background in drug development, oversight or administrative roles, which has been standard for former leaders of the Center for Biologics Evaluation and Research. She has worked at the FDA as a top consultant to the commissioner and the vaccine center since spring.

“She doesn’t seem to have any of the qualifications” for running the drug-regulation department, remarked Dr. Jonathan Howard. “She’s never run a clinical trial. She has no expertise in running a major agency. She has no expertise in industry regulation.”

Previous directors of the center would “understand regulatory frameworks and the research of medication creation”, noted Janet Woodcock. “Frankly, she doesn’t have the kind of background that previous people who headed CBER have had.”

The drug center has an immense range of responsibilities at the FDA, she emphasized.

“The public just focuses on the innovative therapies, but the generic drug division authorizes numerous generic drugs. There’s a biosimilars program, OTC medication office and other areas, and all of those must be managed,” Dr. Woodcock explained. “The thing you overlook, that is the part that I always told people is going to bite you.”

Additionally, a significant administrative component to the position, which oversees more than 5,000 staff members. “It’s a enormous management job, if you perform it correctly,” she concluded.

Response and Disputed Programs

Regarding concerns about Høeg’s qualifications and whether this selection represents increased cooperation among FDA leaders on immunizations, a representative said that the “concerns are based on inaccurate premises”.

“Her resume aligns with the duties of her position,” the representative explained, pointing to the months Dr. Høeg spent guiding the agency head on “medication safety and oversight research, including predictive safety algorithms and shot safety tracking”.

As the temporary head, Dr. Høeg takes over the commissioner’s new fast-track approval initiative, a disputed one-day medication authorization process that reportedly worried her former heads. “How are these medications being picked for this fast-track system? Who makes the choices?” Howard questioned. “There’s a lot of secrecy occurring at the FDA right now.”

Broadly speaking, he said, “the FDA seems to be moving towards less stringent regulations of all drugs, except for vaccines.”

Established History on Vaccines

With immunizations, Dr. Høeg has a clearer, if concerning, history, Howard said. She published a study using unverified volunteer-provided data to estimate the incidence of myocarditis after COVID-19 immunization. She counseled the state of Florida surgeon general Dr. Joseph Ladapo, who reportedly have altered data to suggest Covid vaccines are riskier than they are.

Among her “policy goals” for the incoming administration encompassed changing guidelines for novel immunizations and discontinuing “unnecessary” immunizations, she said after the election on a podcast. At the agency, Høeg has according to sources suggested excluding young men from obtaining COVID-19 vaccinations.

“She is an all-around ideologue who starts off with her conclusions and works backwards to accommodate the evidence in a highly deceptive, dishonest fashion,” Howard stated.

Consolidating Power and a “Revenge Tour”

Høeg joined other skeptics, {like|